Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336266 · ClinicalTrials.gov registry record · Early Phase 1
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
A Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Andrew Hendifar, MD.
- Active
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05336266: Active Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Andrew Hendifar, MD.
NCT05336266 is a Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Andrew Hendifar, MD. The registered enrollment target is 28 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05336266, a Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Andrew Hendifar, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.
Primary Outcome
Defined as 75% or more of patients taking the study medication as prescribed for 5 days in a 6-day period: compliance diary.
Conditions Studied
Interventions
- DRUG Ketorolac Tromethamine
Study Locations (1)
California
- Cedars- Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-12-05 |
| Phase | Early Phase 1 |
What the registry record for NCT05336266 still lists
NCT05336266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ketorolac Tromethamine is the first listed.
NCT05336266 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05336266 about?
NCT05336266 is a clinical study titled "A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma". The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.
What is the current status of trial NCT05336266?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2022-07-01. Estimated completion is 2026-12-05.
What conditions does trial NCT05336266 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreas Cancer.
What interventions are being tested in trial NCT05336266?
The interventions under investigation include: Ketorolac Tromethamine (DRUG).
Who is sponsoring clinical trial NCT05336266?
This trial is sponsored by Andrew Hendifar, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336266 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05336266's enrollment target sits among peer trials
28 199th of 278 higher than 76 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
-
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Lidocaine Infusion in Pancreatic Cancer
RECRUITING · Early Phase 1
-
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI